We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.50 | 0.28% | 1,640.50 | 1,640.00 | 1,640.50 | 1,656.00 | 1,635.00 | 1,642.00 | 5,918,777 | 16:29:57 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
Date | Subject | Author | Discuss |
---|---|---|---|
03/1/2018 14:33 | Yes, and as usual, I intend to buy more GSK with the 19p per share proceeds...... ;0) | tradermichael | |
03/1/2018 14:22 | Yes divi & capital growth, perfect investment here, not surprised investors have twigged! | ny boy | |
03/1/2018 14:19 | Trader 6% dividend while you wait. | montyhedge | |
03/1/2018 14:15 | I'm not excited about 1550p as I have a big block of these at 1732p! Looking forward to the big divi payout next week, though ..... happy 2018 all ....... ;0) | tradermichael | |
03/1/2018 13:49 | GSK look superb, back to 1550p. New shingle's vac is a blockbuster | montyhedge | |
03/1/2018 13:46 | January 3, 2018 NICE has recommended that the NHS should fund GlaxoSmithKline&rsqu | philanderer | |
03/1/2018 12:16 | Monty,Your Filtered for always being a Pratt !!! | garycook | |
03/1/2018 12:16 | Top Picks 2018: Glaxo Smithkline (GSK) | philanderer | |
03/1/2018 12:05 | $40 target thats a 12.77% upside, but with the 6% dividend 18.77% I'm looking for 24.5% return. | montyhedge | |
03/1/2018 10:31 | Fingers crossed, the US research company said 12.77% rise in shareprice but with 6% dividend making 18.77% for 2018 not to bad. I personally looking for 1475p even better return.Fund managers would kill for that 18.77% return. | montyhedge | |
03/1/2018 09:17 | Woodhawk - agreed I also think Emma Walmsley is doing a far better job than is generally appreciated. The thing she needs to develop is her skill set in dealing with a*sehole analysts | ianood | |
03/1/2018 09:01 | Indeed, you're right, Monty, but it doesn't alter my view - I think GSK is worth more. | woodhawk | |
03/1/2018 08:59 | With 12.77% rise in shareprice forecast and 6% dividend, 18.77% return not to bad for 2018. | montyhedge | |
03/1/2018 08:56 | I think Zack is rather parsimonious, Monty. I'm looking for rather more. | woodhawk | |
03/1/2018 08:43 | BUY from US Zacks Investment Research, saying 12.77% upside in shareprice. | montyhedge | |
03/1/2018 08:35 | I topped up on the last dip so it's well above my ave now :) | gbh2 | |
03/1/2018 08:27 | Nice move up this morning. | woodhawk | |
03/1/2018 08:03 | Fair value around 1475p. | montyhedge | |
02/1/2018 22:39 | See above post. | eeza | |
02/1/2018 22:31 | Closing price of ADRs equivalent to about 13.55 and half of that rise was post LSE close. A very strong performance given no news. | polaris | |
02/1/2018 22:02 | The ADRs were up 2% when London shut with GSK down.mostly a rise in the £/$ exchange rate. | dr biotech | |
02/1/2018 18:55 | What a boring and irrelevant topic this board pursues on GSK., more importantly the US ADR’s are up nigh on 4% this evening, that is what should drive the price, not a subject that has been dormant for a quarter of a century. GSK depends on more important research than CJD! | wormhasturned |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions